EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys

Kimberley Talbot, Jina Song, John R Perrier, Shannon Jackson, Ross T A MacGillivray, Edward L G Pryzdial iD

Haemophilia · 2024

DOI: 10.1111/hae.15087 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Haemophilia, 2024. Verfasst von Kimberley Talbot und 5 weiteren Autor:innen. Beteiligte Einrichtung: Canadian Blood Services, Medical Affairs and Innovation, Vancouver, Canada. Hauptthemen laut MEDLINE: Thrombin, Heterozygote. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Heart and Stroke Foundation of Canada, Canadian Blood Services Discovery Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Congenital factor V (FV) deficiency is a rare clotting disorder affecting ∼1 in 1,000,000, with bleeding severity that ranges broadly for poorly understood reasons.

Aim

To help understand the molecular basis of the observed phenotype in FV deficient patients, the genetics and biochemistry causing a patient's FV deficiency were evaluated. Methods and Results A 71‐year‐old female, who had serious life‐long bleeding upon provocation and profound menorrhagia that lead to hysterectomy, was found to have 3% of normal plasma FV antigen with normal electrophoretic mobility. Platelet FV was similarly low, although the banding pattern was less fragmented than normal. Plasma clotting activity was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombinHeterozygoteHumansFemaleAgedFactor VMutation, MissenseMutationFactor V DeficiencyHemostasis

Stichwörter der Autor:innen

bleeding disordercoagulation deficiencyfactor Vthrombin

Substanzen

ThrombinFactor V

Autor:innen und Institutionen

  • Canadian Blood Services, Medical Affairs and Innovation, Vancouver, Canada.
  • University of British Columbia (UBC), Centre for Blood Research, Vancouver, Canada.
  • Department of Pathology and Laboratory Medicine, UBC, Vancouver, Canada.
  • Hematology, St. Paul's Hospital, Providence Health Care, Vancouver, Canada.
  • Department of Medicine, UBC, Vancouver, Canada.
  • Department of Biochemistry and Molecular Biology, UBC, Vancouver, Canada.

ORCID-Profile: Edward L G Pryzdial

Förderung

  • Heart and Stroke Foundation of Canada
  • Canadian Blood Services Discovery Research Grant

Zitieren

APA

Talbot, K., Song, J., Perrier, J. R., Jackson, S., MacGillivray, R. T. A., & Pryzdial, E. L. G. (2024). Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys. Haemophilia. https://doi.org/10.1111/hae.15087

Vancouver

Talbot K, Song J, Perrier JR, Jackson S, MacGillivray RTA, Pryzdial ELG. Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys. Haemophilia. 2024. doi:10.1111/hae.15087

BibTeX
@article{Talbot2024,
  author = {Talbot, Kimberley and Song, Jina and Perrier, John R and Jackson, Shannon and MacGillivray, Ross T A and Pryzdial, Edward L G},
  title = {Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys},
  journal = {Haemophilia},
  year = {2024},
  doi = {10.1111/hae.15087}
}
Kostenlos starten →